• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将生产率纳入考量以反映治疗价值:已发表的卫生经济评估系统综述

Including Productivity as an Element to Reflect Value of the Treatment: A Systematic Review of Published Health Economic Evaluations.

作者信息

Mamiya Hiroaki, Wattanakamolkul Kittima, Li Nan, Wu David Bin-Chia, Hirozane Mariko, Igarashi Ataru

机构信息

Department of Pharmaceutical Sciences, International University of Health and Welfare, Narita city, Chiba, Japan.

Value, Evidence and Access Department, Integrated Market Access, Johnson and Johnson, Tokyo, Japan.

出版信息

Pharmacoecon Open. 2025 Jun 24. doi: 10.1007/s41669-025-00589-9.

DOI:10.1007/s41669-025-00589-9
PMID:40553408
Abstract

BACKGROUND

Productivity is utilised inconsistently in value assessment and poses methodological and conceptual challenges for estimation. This systematic literature review aims to understand how productivity gain/loss for patients and caregivers was measured in health economic evaluation, identify the preferred instruments to capture productivity gain/loss and assess their properties.

METHODS

A systematic literature review was conducted using PubMed, Ovid MEDLINE, Embase, Japan-specific (J-STAGE and Ichushi Web) and economic literature databases (Cost-Effectiveness Analysis (CEA) Registry, Paediatric Economic Database Evaluation (PEDE) and National Health Service Economic Evaluation Database (NHS EED)). Additional relevant data were identified using clinical trial registries and grey literature searches. Studies published between January 2021 and December 2023 which presented economic evaluations with outcomes relevant to productivity measures were included. Instruments were selected for practical relevance and frequent use in studies, while research-specific and single-study questionnaires were excluded.

RESULTS

Among 1431 published health economic evaluations with productivity in the assessment, 152 were included in this review. These studies were almost equally distributed over the 3-year period, with a slightly higher number in 2023 versus 2021 [54 (35.5%) versus 48 (31.6%)]. In total, 118/152 studies reported patient measures only, 14/152 reported caregiver measures only and 20/152 reported both patient and caregiver measures. Based on the inclusion criteria, 20 of the 88 identified instruments were further investigated in this review. The Work Productivity and Activity Impairment Questionnaire (WPAI) [23 (15.1%)], Institute for Medical Technology Assessment (iMTA) Productivity Cost Questionnaire (iPCQ) [23 (15.1%)] and Trimbos/iMTA Questionnaire for Costs associated with Psychiatric Illness​ (TIC-P) [(8 (5.3%)] were the most commonly used instruments. All three instruments were reported as valid and reliable. All three instruments reported absenteeism, presenteeism and overall work impairment. WPAI additionally included information on daily activity impairment. The human capital approach (n = 18) and the friction cost approach (n = 17) were utilised to assign monetary value to the lost productivity.

CONCLUSIONS

This review identified a significant number of health economic evaluations between 2021 and 2023, which included productivity loss in the assessment. Various instruments were used to measure productivity loss in these studies, while a few instruments were commonly used across studies. To ensure consistent measurement of productivity, it is crucial to establish a standard tailored to a country or region, considering differences across countries or regions. Furthermore, necessary adaptations should be made on the basis of the specific health intervention being studied. Last, maintaining transparency in all productivity evaluations is vital.

摘要

背景

在价值评估中,生产力的运用并不一致,这给估算带来了方法和概念上的挑战。本系统文献综述旨在了解在健康经济评估中如何衡量患者和照护者的生产力增减,确定用于衡量生产力增减的首选工具,并评估其特性。

方法

使用PubMed、Ovid MEDLINE、Embase、日本特有的数据库(J-STAGE和Ichushi Web)以及经济文献数据库(成本效益分析(CEA)注册库、儿科经济数据库评估(PEDE)和国家卫生服务经济评估数据库(NHS EED))进行系统文献综述。通过临床试验注册库和灰色文献检索确定了其他相关数据。纳入了2021年1月至2023年12月期间发表的、呈现与生产力衡量相关结果的经济评估研究。选择工具是基于其实际相关性和在研究中的频繁使用情况,同时排除特定研究和单研究问卷。

结果

在1431项已发表的包含生产力评估的健康经济评估中,本综述纳入了152项。这些研究在三年期间分布大致均匀,2023年的数量略多于2021年[54项(35.5%)对48项(31.6%)]。总共,152项研究中有118项仅报告了患者指标,14项仅报告了照护者指标,20项报告了患者和照护者指标。根据纳入标准,本综述对88种已识别工具中的20种进行了进一步研究。工作生产力与活动障碍问卷(WPAI)[23项(15.1%)]、医学技术评估研究所(iMTA)生产力成本问卷(iPCQ)[23项(15.1%)]和Trimbos/iMTA精神疾病相关成本问卷(TIC-P)[8项(5.3%)]是最常用的工具。所有这三种工具都被报告为有效且可靠。所有三种工具都报告了旷工、出勤主义和总体工作障碍。WPAI还包括了关于日常活动障碍的信息。人力资本法(n = 18)和摩擦成本法(n = 17)被用于为损失的生产力赋予货币价值。

结论

本综述发现2021年至2023年间有大量健康经济评估,其中评估中包含生产力损失。在这些研究中使用了各种工具来衡量生产力损失,同时有几种工具在各研究中普遍使用。为确保生产力的一致衡量,考虑到国家或地区间的差异,制定适合某个国家或地区的标准至关重要。此外,应根据所研究的具体健康干预措施进行必要的调整。最后,在所有生产力评估中保持透明度至关重要。

相似文献

1
Including Productivity as an Element to Reflect Value of the Treatment: A Systematic Review of Published Health Economic Evaluations.将生产率纳入考量以反映治疗价值:已发表的卫生经济评估系统综述
Pharmacoecon Open. 2025 Jun 24. doi: 10.1007/s41669-025-00589-9.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
5
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.在没有明显临床指征的患者和常见合并症患者亚组中,在择期手术前常规检测全血细胞计数、电解质和尿素以及肺功能测试的价值:对临床和成本效益文献的系统评价。
Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500.
6
Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation.左心室辅助装置作为晚期心力衰竭的终末期治疗的临床和成本效益:系统评价和经济评估。
Health Technol Assess. 2024 Aug;28(38):1-237. doi: 10.3310/MLFA4009.
7
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.拓扑替康、聚乙二醇化脂质体盐酸多柔比星和紫杉醇用于晚期卵巢癌二线或后续治疗:一项系统评价和经济学评估
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090.
8
The clinical effectiveness and cost-effectiveness of low-intensity psychological interventions for the secondary prevention of relapse after depression: a systematic review.低强度心理干预在预防抑郁复发中的临床效果和成本效益:系统评价。
Health Technol Assess. 2012 May;16(28):1-130. doi: 10.3310/hta16280.
9
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.
10
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.

本文引用的文献

1
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.重视药品和其他卫生技术的社会影响:当前最佳实践用户指南。
Forum Health Econ Policy. 2024 Nov 8;27(1):29-116. doi: 10.1515/fhep-2024-0014. eCollection 2024 Jun 1.
2
Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders.免疫介导性疾病成本效益分析中使用生产力损失/增益的系统文献回顾。
Adv Ther. 2022 Dec;39(12):5327-5350. doi: 10.1007/s12325-022-02321-z. Epub 2022 Oct 7.
3
Caregiving-Related Work Productivity Loss Among Employed Family and Other Unpaid Caregivers of Older Adults.
照顾老年人的家庭和其他无酬照顾者的与照顾相关的工作生产力损失。
Value Health. 2023 May;26(5):712-720. doi: 10.1016/j.jval.2022.06.014. Epub 2022 Aug 13.
4
Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective.有偿和无偿工作生产力损失的测量工具:从社会角度对健康经济评估适用性的系统评价与评估
Value Health. 2021 Nov;24(11):1686-1699. doi: 10.1016/j.jval.2021.05.002. Epub 2021 Sep 17.
5
Comparison of self-reported and public registered absenteeism among people on long-term sick leave due to musculoskeletal disorders: criterion validity of the iMTA Productivity Cost Questionnaire.比较因肌肉骨骼疾病长期请病假人群的自我报告和公共登记缺勤情况:iMTA 生产力成本问卷的效标效度。
Eur J Health Econ. 2021 Aug;22(6):865-872. doi: 10.1007/s10198-021-01294-0. Epub 2021 Jun 1.
6
Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Portugal.葡萄牙心血管事件相关的患者和照护者生产力损失及间接成本。
Rev Port Cardiol (Engl Ed). 2021 Feb;40(2):109-115. doi: 10.1016/j.repc.2020.05.019. Epub 2021 Feb 10.
7
The effectiveness and cost-effectiveness of assistive technology and telecare for independent living in dementia: a randomised controlled trial.辅助技术和远程护理在痴呆症患者独立生活中的效果和成本效益:一项随机对照试验。
Age Ageing. 2021 May 5;50(3):882-890. doi: 10.1093/ageing/afaa284.
8
Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review.药物成本效益分析中使用生产效率损失/增益:系统评价。
Pharmacoeconomics. 2021 Jan;39(1):81-97. doi: 10.1007/s40273-020-00986-4. Epub 2020 Nov 24.
9
Economic burden of Alzheimer disease and managed care considerations.阿尔茨海默病的经济负担和管理式医疗考虑因素。
Am J Manag Care. 2020 Aug;26(8 Suppl):S177-S183. doi: 10.37765/ajmc.2020.88482.
10
Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.类风湿关节炎的经济负担:生物制剂时代文献的系统回顾。
Ann Rheum Dis. 2020 Jun;79(6):771-777. doi: 10.1136/annrheumdis-2019-216243. Epub 2020 Apr 3.